

COVID-19 Vaccine (Vero Cell), Inactivated (Brief Edition)

This is the Conditional Marketing Authorization, please refer to the instruction and use under the doctor guidance.

[NAME OF THE MEDICAL PRODUCT]

Generic Name: COVID-19 Vaccine (Vero Cell), Inactivated
Trade Name: CoronaVac
Chinese Phonetic Alphabet: Xinxing Guanzhuang Bingdu Miehuyimiao (Vero Xibao)

[COMPOSITION]

Active ingredient: Inactivated SARS-CoV-2 Virus (CZ02 strain)
Adjuvant: Aluminum hydroxide
Excipients: disodium hydrogen phosphate dodecahydrate, sodium dihydrogen phosphate monohydrate, sodium chloride.

[DESCRIPTION]

CoronaVac is a milky-white suspension. Stratified precipitate may form which can be dispersed by shaking.

[TARGET GROUPS FOR VACCINATION]

Susceptible people aged 18 and above.
In Brazil phase III clinical trial, only 5.10% participants enrolled was 60 years and above, hence, the efficacy evidence of people aged 60 and above is insufficient. The subsequent clinical trials will be carried out for further evaluation of efficacy in this population. Data from conducted clinical trials showed that neutralizing antibodies would be induced after vaccination. When use CoronaVac among people aged 60 and above by relevant institutions, the health status and exposure risk of people aged 60 and above shall be considered.

[THERAPEUTIC INDICATION]

CoronaVac is indicated for active immunization against diseases caused by SARS-CoV-2 virus.
Based on the efficacy results for two months from overseas phase III clinical trial, a conditional marketing authorization (CMA) for CoronaVac has been issued. The final efficacy data are not yet available; hence, the efficacy and safety results need to be further confirmed.

[PRESENTATION]

Each vial (syringe) contains 0.5 mL. Single dose of 0.5 mL contains 600SU of inactivated SARS-CoV-2 virus as antigen.

[ADMINISTRATION AND SCHEDULE]

Two doses should be administered for primary immunization. The second dose is preferably given 28 days after the first dose. 0.5 mL per dose.
CoronaVac should be administered by intramuscular injection in the deltoid region of the upper arm. Shake well before use. It has not been determined whether this product requires booster immunization.

[ADVERSE REACTIONS]

The safety of CoronaVac was evaluated in 4 clinical trials conducted domestic and overseas, including randomized, double-blind, placebo-controlled phase I/II clinical trials in people aged 18-59 years and in elderly aged 60 years and above, a phase III clinical efficacy trial in Brazilian health professionals aged 18 years and above, and a phase IIIb bridging trial in different production scales and different populations. Systematic safety observation was carried out within 7 days after each vaccination, and adverse events were collected by voluntary report of subjects and regular follow-up of investigators on 8-14/28 days, long-term of serious adverse events within 12 months after the full vaccination is still ongoing.

General description of adverse reactions in clinical trials and post-authorisation experience of this product

A total of 14,572 subjects aged 18 and above were enrolled in a series of clinical trials conducted domestic and overseas, of which 7,658 subjects received at least one dose. All subjects have completed at least 28 days follow-up after full immunization, and long-term safety visits are ongoing.

According to the grading standard of adverse reaction incidence from Council for International Organizations of Medical Sciences (CIOMS), i.e. very common ($\geq 10\%$), common (1%-10%, 1% was inclusive), uncommon (0.1%-1%, 0.1% was inclusive), rare (0.01%-0.1%, 0.01% was inclusive) and very rare ($<0.01\%$), all adverse reactions were summarized and described as follows.

1. Adverse reactions at injection site

Very common: pain
Common: swelling, pruritus, erythema, induration
Uncommon: burn at injection site

2. Systemic adverse reactions

Very common: headache, fatigue
Common: myalgia, nausea, diarrhea, arthralgia, cough, chills, pruritus, loss of appetite, rhinorrhea, sore throat, nasal congestion, abdominal pain
Uncommon: vomit, hypersensitivity, abnormal skin and mucosa, fever, tremor, flushing, edema, dizziness, drowsiness
Rare: muscle spasms, eyelid edema, nose bleeds/epistaxis, abdominal distension, constipation, hyposmia, ocular congestion, hot flashes, hiccup, conjunctival congestion
Very rare: Bell's palsy*

* Adverse reaction observed post-authorisation in Hong Kong

3. Severity of adverse reactions

The severity of adverse reactions observed in these clinical trials is mainly Grade 1 (mild), the incidence rate of adverse reactions for Grade 3 and the above was 1.31%.
Grade 3 and above adverse reactions includes pain at injection site, cough, fever, headache, sore throat, abdominal pain, dizziness and drowsiness.

4. Serious adverse event (SAE)

No serious adverse event related to vaccination was identified up to February 3, 2021.

[For detailed information of adverse reactions among these clinical trials, please refer to the complete version of the leaflet.](#)

[CONTRAINDICATIONS]

1. People with history of allergic reaction to CoronaVac or other inactivated vaccine, or any component of CoronaVac (active or inactive ingredients, or any material used in the process);
2. Previous severe allergic reactions to the vaccine (eg, acute anaphylaxis, angioedema, dyspnea, etc.);
3. People with severe neurological conditions (eg, transverse myelitis, Guillain-Barré syndrome, demyelinating diseases, etc.);

4. Patients with uncontrolled severe chronic diseases;
5. Pregnant and lactating women.

[PRECAUTIONS]

1. Due to the insufficient data of protection persistence, necessary protective measures should be taken in line with the COVID-19 epidemic.
2. Due to the insufficient data of efficacy in people aged 60 and above. When use CoronaVac among people aged 60 and above by relevant institutions, the health status and exposure risk of people aged 60 and above shall be considered.
3. This vaccine is strictly prohibited for intravenous injection. There is no safety and efficacy data of subcutaneous or intradermal injection.
4. Before use, check whether the packaging container, label, appearance and validity period meet the requirements or not. Do not use if there are cracks in the vial, spots, stains and scratches on the outer surface of the vial, label is not clear or more than the expiration date and abnormal appearance.
5. Avoid expose CoronaVac to the disinfectant during use.
6. This product should be stored at places out of reach of children.
7. Adequate treatment provisions, including epinephrine injection and emergency treatment, should be available for immediate use. Individuals should be observed for at least 30 minutes on site after vaccination.
8. Do not mix with other vaccines in the same syringe.
9. Do not freeze. It shall be administered immediately after open.
10. Patients with acute diseases, acute exacerbation of chronic diseases, severe chronic diseases, atopy and fever should be used with caution; if necessary, delay vaccination after doctor's evaluation.
11. Patients with diabetes, or history of convulsions, epilepsy, encephalopathy or mental illness, or family history of those diseases should be used with caution.
12. Patients with thrombocytopenia or hemorrhagic diseases, intramuscular injection of this product may cause bleeding, so it should be used with caution.
13. The safety and efficacy data of this product on people with impaired immune function (such as malignant tumor, nephrotic syndrome, AIDS patients) have not been obtained, and the vaccination of this product should be based on individual considerations.
14. The injection of human immunoglobulin should be given at least one month interval to avoid affecting the immune effect.
15. No clinical study has been carried out on the evaluation of immune response with other vaccines on the immunogenicity at the same time (before, after or at the same time). Professionals should be consulted when concomitant use.
16. Do not use if there is any adverse reaction of nervous system after inoculation.
17. Like other vaccines, the protective effect may not reach 100% for all recipients.
18. Based on the findings of "False COVID-19 cases due to contamination by inactivated virus vaccine" published in the *Clinical Infectious Diseases*, and the immunogenicity study conducted by Sinovac, the adaptive deletions (as showed by whole-genome sequencing) on the spike protein of Inactivated SARS-CoV-2 Virus (CZ02 strain) of CoronaVac do not change its safety, antigenicity and efficacy.

[SPECIAL POPULATION MEDICATION]

1. Women of childbearing age: the data collected of women with unexpected pregnancy after vaccination from clinical trials are very limited, which is not enough to decide the risk of adverse pregnancy outcomes after vaccination.
2. Pregnant or lactating women: the clinical data of pregnant and lactating women are not available at present.
3. People aged 60 and above: the immunogenicity and safety data from conducted clinical trials have been obtained, while the efficacy data from phase III clinical trial is insufficient.

[DRUG-DRUG INTERACTIONS]

1. Concomitant use with other vaccines: no clinical study has been carried out on the evaluation of immune response with other vaccines on the immunogenicity at the same time (before, after or at the same time).
2. Concomitant use with other drugs: immunosuppressive drugs, such as immunosuppressive drugs, chemotherapy drugs, antimetabolic drugs, alkylating agents, cytotoxic drugs, corticosteroid drugs, etc., may reduce the immune response to this product.
3. Patients undergoing treatment: for patients undergoing treatment, please consult the professional doctors before use CoronaVac to avoid possible drug interactions.

[STORAGE]

Store and transport between +2-8°C, and protect from light.

[SHELF LIFE]

The shelf life of the vaccine is tentatively scheduled as 12 months.

[PACKAGE]

This product is packaged into vial, 40 vials per box.

[SPECIFICATION IMPLEMENTED]

YBS00152021

[MARKETING AUTHORIZATION HOLDER]

Name: Sinovac Life Sciences Co., Ltd.

Registered address: Building 1, No. 21, Tianfu Street, Daxing Biomedicine Industrial Base of Zhongguancun Science Park, Daxing District, Beijing, P.R.China

[MANUFACTURER]

Name: Sinovac Life Sciences Co., Ltd.

Address: No. 21, Tianfu Street, Daxing Biomedicine Industrial Base of Zhongguancun Science Park, Daxing District, Beijing, P.R.China




Postal code: 102601

Tel.: 86-10-56897188

Fax: 86-10-56897123

Website: www.sinovac.com

E-mail: sinovac@sinovac.com

客户名称	北京科兴中维生物技术有限公司	产品名称及版本号	说明书(新型冠状病毒灭活疫苗(Vero细胞)西林瓶英文上市版40瓶装)CX-03-03B-X(40en)		
成品尺寸(mm)	120x210	发送次数	改动内容	制作员	bf
盒型		11	<input checked="" type="checkbox"/> 文字 <input type="checkbox"/> 版式 <input type="checkbox"/> 尺寸	工艺员	
打印日期	2021.9.16		<input type="checkbox"/> 盒型 <input type="checkbox"/> 颜色	质检员	
请您在确认稿件内容无误后签字确认： <input type="checkbox"/> 颜色 <input type="checkbox"/> 文字 <input type="checkbox"/> 版式 <input type="checkbox"/> 成品尺寸 <input type="checkbox"/> 条形码			客户签字： 日期：		
备注：  色样桔色  PANTONE 2035C  K100%			北京宝岛包装印刷有限公司		